摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl)sulfanyl]N-cyclopropylacetamide | 503437-96-5

中文名称
——
中文别名
——
英文名称
2-[(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl)sulfanyl]N-cyclopropylacetamide
英文别名
2-[(2-anilino-7-methyl4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl)sulfanyl]-N-cyclopropylacetamide;2-[(2-anilino-7-methyl-4-oxo-1-phenyl-1,6-naphthyridin-5-yl)sulfanyl]-N-cyclopropylacetamide
2-[(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl)sulfanyl]N-cyclopropylacetamide化学式
CAS
503437-96-5
化学式
C26H24N4O2S
mdl
——
分子量
456.568
InChiKey
VHFCVCUBKFRPMV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    694.9±55.0 °C(Predicted)
  • 密度:
    1.37±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    33
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    99.6
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS<br/>[FR] DERIVES 1, 8-NAPHTYRIDINE UTILISES COMME ANTIDIABETIQUES
    申请人:BAYER AG
    公开号:WO2003027112A1
    公开(公告)日:2003-04-03
    The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C-R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    本发明涉及公式的萘啶衍生物,其中U、X、Y和Z中的一个是氮,其余为C-R,其中R是氢或取代基。更具体地,本发明涉及1,8-萘啶衍生物和含有这种衍生物的药物组合物。本发明的方法包括给予本发明的萘啶衍生物治疗糖尿病及相关疾病。
  • [EN] 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS<br/>[FR] DERIVES DE 1,6-NAPHTHYRIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU DIABETE ET DE TROUBLES ASSOCIES
    申请人:BAYER AG
    公开号:WO2003027113A1
    公开(公告)日:2003-04-03
    The invention relates generally to naphthyridine derivatives of the formula (A), wherein one of U, X, Y and Z is nitrogen and the others are C-R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    本发明涉及公式(A)的萘啶衍生物,其中U、X、Y和Z中的一个是氮,其他为C-R,其中R是氢或取代基。更具体地,本发明涉及1,6-萘啶衍生物和含有这种衍生物的药物组合物。本发明的方法包括给予本发明的萘啶衍生物治疗糖尿病及相关疾病。
  • 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders
    申请人:Bayer Pharmaceuticals Corporation
    公开号:US20040209866A1
    公开(公告)日:2004-10-21
    The invention relates generally to naphthyridine derivatives of the formula 1 wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    本发明涉及公式1的萘啶衍生物,其中U、X、Y和Z中的一个是氮,其他为C—R,其中R为氢或取代基。更具体地,本发明涉及1,8-萘啶衍生物和含有这种衍生物的制药组合物。本发明的方法包括给予本发明的萘啶衍生物治疗糖尿病及相关疾病。
  • 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders
    申请人:——
    公开号:US20040014751A1
    公开(公告)日:2004-01-22
    The invention relates generally to naphthyridine derivatives of the formula 1 wherein one of U, X, Y and Z is nitrogen and the others are C-R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    该发明涉及公式1的萘啶衍生物,其中U、X、Y和Z中的一个是氮,其余为C-R,其中R是氢或取代基。更具体地,该发明涉及1,8-萘啶衍生物和含有这种衍生物的药物组合物。该发明的方法包括给予该发明的萘啶衍生物治疗糖尿病及相关疾病。
  • 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders
    申请人:Bayer Pharmaceuticals Corporation
    公开号:US20040157875A1
    公开(公告)日:2004-08-12
    The invention relates generally to naphthyridine derivatives of the formula 1 wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    本发明涉及公式1的萘啶衍生物,其中U、X、Y和Z中的一个是氮,其余的是C-R,其中R是氢或取代基。更具体地,本发明涉及1,6-萘啶衍生物和含有这种衍生物的制药组合物。本发明的方法包括给予本发明的萘啶衍生物,以治疗糖尿病和相关疾病。
查看更多